Pharmaceuticals

Tysabri (natalizumab) Market 2026 driven by multiple sclerosis treatment advancements

March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Tysabri (natalizumab) Market From 2026 To 2030?

The market size for tysabri (natalizumab) has demonstrated robust growth in recent years. It is projected to increase from $2.66 million in 2025 to $2.87 million in 2026, at a compound annual growth rate (CAGR) of 8.1%. This historical growth can be ascribed to several factors, including increasing multiple sclerosis prevalence, the approval of natalizumab therapy, its adoption by neurologists, the unmet need in aggressive MS, and the expansion of infusion centers.

The tysabri (natalizumab) market size is projected to experience robust expansion over the coming years, with its value set to reach $3.87 million by 2030, reflecting a compound annual growth rate (CAGR) of 7.8%. This anticipated growth during the forecast period is primarily fueled by factors such as an increase in MS diagnosis rates, enhancements in infusion infrastructure, improved risk mitigation programs, the expansion of specialty neurology services, and sustained support from long-term clinical outcomes. Concurrently, significant trends for this period include the rising application of monoclonal antibodies in MS treatment, a growing preference for high-efficacy disease-modifying therapies, the widening availability of outpatient infusion care, the implementation of more advanced safety and risk monitoring protocols, and an increased focus on the management of progressive MS.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19942&type=smp

What Key Drivers Are Influencing The Growth Of The Tysabri (natalizumab) Market?

The tysabri (natalizumab) market is anticipated to expand due to an increase in autoimmune disorders. These disorders involve the immune system mistakenly attacking the body’s own components, leading to inflammation, damage, and chronic conditions like rheumatoid arthritis or multiple sclerosis, stemming from genetic and environmental influences. The growing occurrence of autoimmune disorders can be attributed to genetic predispositions, environmental factors, and enhanced diagnostic capabilities and public awareness, which result in more identified cases. Tysabri effectively treats autoimmune disorders by targeting particular immune cells, thereby inhibiting inflammation and damage, proving beneficial for conditions such as multiple sclerosis and Crohn’s disease. An example from February 2024, shared by Arthritis Australia, indicates that around 562,378 Australians are projected to have rheumatoid arthritis (RA) by 2025, making up 14% of the entire arthritis population. Consequently, the rising prevalence of autoimmune disorders is a significant driver for the tysabri (natalizumab) market. The expansion of personalized medicine is projected to boost the tysabri (natalizumab) market. Personalized medicine represents a healthcare strategy that customizes treatments and care plans based on a patient’s unique attributes, such as their genetic makeup, surroundings, and daily habits, aiming for optimal and precise results. This increase in personalized medicine can be attributed to progress in genomic technologies, a deeper comprehension of molecular biology, the growing accessibility of accurate diagnostic tools, and a desire for targeted therapies that enhance patient recovery while reducing side effects. Tysabri (natalizumab) serves as a prime illustration of personalized medicine principles, providing a focused treatment method for relapsing multiple sclerosis, specifically adapted for patients with particular disease activity and risk profiles, thereby enhancing therapeutic effectiveness and mitigating potential negative reactions. For example, the Personalized Medicine Coalition, a US-based non-profit, reported in February 2024 that the FDA cleared 16 new personalized treatments for rare diseases in 2023, an increase from six in 2022. These approvals also encompassed seven drugs for cancer and three for various other conditions. Consequently, the growth of personalized medicine is propelling the tysabri (natalizumab) market.

Which Segments Are Included In The Analysis Of The Tysabri (natalizumab) Market?

The tysabri (natalizumab) market covered in this report is segmented –

1) By Clinical Indication: Multiple Sclerosis, Crohn’s Disease

2) By Patient Setting: Inpatient, Outpatient

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Trends Are Impacting The Growth Of The Tysabri (natalizumab) Market?

Leading companies in the tysabri (natalizumab) market are focusing on broadening treatment options through alternative solutions, such as biosimilars, to provide patients with more effective therapies that improve their quality of life and disease management. Biosimilars to Tysabri offer an economical alternative for treating highly active relapsing-remitting multiple sclerosis, thereby increasing access to essential treatment, especially in underserved regions. For instance, in January 2024, Sandoz Group AG, a pharmaceutical company based in Switzerland, introduced Tyruko (natalizumab), the first and only biosimilar to Tysabri, intended for the treatment of adults with highly active relapsing-remitting multiple sclerosis (RRMS). This launch strengthens Sandoz’s biosimilar portfolio and aims to improve access to effective and affordable treatments for individuals living with multiple sclerosis.

Which Key Industry Participants Are Active In The Tysabri (natalizumab) Market?

Major companies operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, Polpharma Biologics

Read the full tysabri (natalizumab) market report here:

https://www.thebusinessresearchcompany.com/report/tysabri-natalizumab-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Tysabri (natalizumab) Market?

North America was the largest region in the tysabri (natalizumab) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tysabri (natalizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Tysabri (natalizumab) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19942&type=smp

Browse Through More Reports Similar to the Global Tysabri (natalizumab) Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Tylosin Market Report 2026

https://www.thebusinessresearchcompany.com/report/tylosin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795